(Reuters) -Praxis Precision Medicines said on Friday an independent committee had recommended that its tremor drug trial be stopped for futility, as the trial was unlikely to meet the main goal. Shares of the company fell 40% in premarket trading. The Independent Data Monitoring Committee indicated that some underlying assumptions of the statistical model might […]
Health
Praxis’ tremor drug trial unlikely to meet main goal
Audio By Carbonatix
(Reuters) -Praxis Precision Medicines said on Friday an independent committee had recommended that its tremor drug trial be stopped for futility, as the trial was unlikely to meet the main goal.
Shares of the company fell 40% in premarket trading.
The Independent Data Monitoring Committee indicated that some underlying assumptions of the statistical model might have influenced this outcome and encouraged Praxis to explore alternative analysis methods.
Praxis said it had decided to continue the trials to completion given the advanced stage of patient enrollment and the advice received from the committee.
The experimental drug, ulixacaltamide, is in late-stage development for the treatment of essential tremor, a condition that affects the nervous system and causes involuntary and rhythmic shaking.
The company will explore different analysis methods for the final dataset and expects to read out results in the third quarter of 2025.
(Reporting by Sriparna Roy in Bengaluru; Editing by Shreya Biswas)